# Study of DF6215 in Patients With Advanced Solid Tumors

> **NCT06108479** · PHASE1 · COMPLETED · sponsor: **Dragonfly Therapeutics** · enrollment: 35 (actual)

## Conditions studied

- Solid Tumor, Adult
- Solid Tumor Cancer

## Interventions

- **DRUG:** DF6215
- **DRUG:** pembrolizumab
- **DRUG:** KEYTRUDA®

## Key facts

- **NCT ID:** NCT06108479
- **Lead sponsor:** Dragonfly Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-28
- **Primary completion:** 2025-12-04
- **Final completion:** 2025-12-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06108479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06108479, "Study of DF6215 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06108479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*